Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart A Grossman

Showing results (141-150 of 171) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Correction: Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ HybridizationMatthias Holdhoff, Gunes Guner, Fausto J Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2016
Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and <i>In Situ</i> HybridizationMatthias Holdhoff, Gunes Guner, Fausto J Rodriguez, et al.
Neuro-Oncology|February 11, 2004
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposiumRamsis K Benjamin, Fred H Hochberg, Elizabeth Fox, et al.
Cell Reports. Medicine|July 2, 2024
A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)Manmeet S Ahluwalia, Ahmad Ozair, Michelle Rudek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade GliomaKarisa C Schreck, Roy E Strowd, Louis B Nabors, et al.
Neuro-Oncology|April 4, 2017
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomasMatthias Holdhoff, Xiaobu Ye, Jeffrey G Supko, et al.
Neuro-Oncology|June 8, 2020
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug deliveryStuart A Grossman, Carlos G Romo, Michelle A Rudek, et al.
Neuro-Oncology Advances|July 24, 2025
Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade gliomaJian L Campian, Stuart A Grossman, Angela Shaulov Kask, et al.
Neuro-Oncology Advances|October 7, 2024
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastomaMatthias Holdhoff, Xiaobu Ye, Roy E Strowd, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Pageof 18

Showing results (141-150 of 171) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Correction: Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ HybridizationMatthias Holdhoff, Gunes Guner, Fausto J Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2016
Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and <i>In Situ</i> HybridizationMatthias Holdhoff, Gunes Guner, Fausto J Rodriguez, et al.
Neuro-Oncology|February 11, 2004
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposiumRamsis K Benjamin, Fred H Hochberg, Elizabeth Fox, et al.
Cell Reports. Medicine|July 2, 2024
A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)Manmeet S Ahluwalia, Ahmad Ozair, Michelle Rudek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade GliomaKarisa C Schreck, Roy E Strowd, Louis B Nabors, et al.
Neuro-Oncology|April 4, 2017
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomasMatthias Holdhoff, Xiaobu Ye, Jeffrey G Supko, et al.
Neuro-Oncology|June 8, 2020
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug deliveryStuart A Grossman, Carlos G Romo, Michelle A Rudek, et al.
Neuro-Oncology Advances|July 24, 2025
Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade gliomaJian L Campian, Stuart A Grossman, Angela Shaulov Kask, et al.
Neuro-Oncology Advances|October 7, 2024
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastomaMatthias Holdhoff, Xiaobu Ye, Roy E Strowd, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Pageof 18